BioMarin Pharma (BMRN)
66.53
+0.10 (0.15%)
Upcoming Events
Latest Headlines
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $90; Piper Sandler: 'Remain Buyers'
September 1, 2026 7:30 AM - StreetInsider
Canaccord Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)
September 1, 2026 6:58 AM - StreetInsider
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $60 at H.C. Wainwright
August 31, 2026 11:02 AM - StreetInsider
Morgan Stanley on BioMarin Pharmaceutical Inc. (BMRN): 'we think the settlement recognizes the value of BioMarin’s pioneering CNP innovation'
August 31, 2026 11:01 AM - StreetInsider
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Jefferies
August 31, 2026 11:00 AM - StreetInsider
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $109 at Raymond James
August 31, 2026 9:32 AM - StreetInsider
Stifel Reiterates Hold Rating on BioMarin Pharmaceutical Inc. (BMRN)
August 31, 2026 9:22 AM - StreetInsider
Piper Sandler on BioMarin Pharmaceutical Inc. (BMRN): 'We Remain Bullish After Hosting Management Meetings'
August 26, 2026 9:22 AM - StreetInsider
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $59 at H.C. Wainwright
August 19, 2026 6:43 AM - StreetInsider
Canaccord Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)
August 19, 2026 6:34 AM - StreetInsider
BMO Capital Starts BioMarin Pharmaceutical Inc. (BMRN) at Outperform
August 18, 2026 4:13 PM - StreetInsider
Form 8-K BIOMARIN PHARMACEUTICAL For: Aug 17
August 18, 2026 8:39 AM - SEC Filing
BioMarin to acquire Alesta Therapeutics for $275M upfront
August 18, 2026 8:31 AM - StreetInsider
BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline
August 18, 2026 8:30 AM - PR NewsWire
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $88 at Piper Sandler
August 17, 2026 7:43 AM - StreetInsider
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $111 at Barclays
August 17, 2026 4:51 AM - StreetInsider
BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston
August 10, 2026 9:05 AM - PR NewsWire
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $114 at Canaccord
August 10, 2026 7:00 AM - StreetInsider
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $70 at Stifel
August 7, 2026 10:22 AM - StreetInsider
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $97 at Oppenheimer
August 7, 2026 6:17 AM - StreetInsider
Form S-8 BIOMARIN PHARMACEUTICAL
August 6, 2026 5:26 PM - SEC Filing
BioMarin Pharma (BMRN) Tops Q2 EPS by 25c
August 6, 2026 5:13 PM - StreetInsider
Form 10-Q BIOMARIN PHARMACEUTICAL For: Jun 30
August 6, 2026 4:20 PM - SEC Filing
Form 8-K BIOMARIN PHARMACEUTICAL For: Aug 06
August 6, 2026 4:07 PM - SEC Filing
BioMarin Reports Second Quarter 2026 Financial and Operating Results
August 6, 2026 4:03 PM - PR NewsWire
BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET
July 30, 2026 9:00 AM - PR NewsWire
H.C. Wainwright Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)
July 29, 2026 6:49 AM - StreetInsider
BioMarin and n-Lorem partner to develop ASO treatment for ReNU syndrome
July 27, 2026 9:05 AM - StreetInsider
BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome
July 27, 2026 9:05 AM - PR NewsWire
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $76 at Citi
July 16, 2026 5:03 AM - StreetInsider
H.C. Wainwright Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)
July 14, 2026 6:57 AM - StreetInsider
BioMarin completes acquisition of Amicus Therapeutics
July 13, 2026 4:15 PM - StreetInsider
Form 8-K/A BIOMARIN PHARMACEUTICAL For: Apr 27
July 13, 2026 4:07 PM - SEC Filing
FDA accepts BioMarin's application for full approval of achondroplasia drug
July 13, 2026 9:05 AM - StreetInsider
U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia
July 13, 2026 9:05 AM - PR NewsWire
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $62 at RBC Capital
July 7, 2026 7:59 AM - StreetInsider
Stifel Reiterates Hold Rating on BioMarin Pharmaceutical Inc. (BMRN)
June 22, 2026 9:25 AM - StreetInsider
H.C. Wainwright Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)
June 22, 2026 6:58 AM - StreetInsider
BioMarin shares VOXZOGO three-year data and BMN 333 Phase 1 results
June 16, 2026 9:05 AM - StreetInsider
BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026
June 16, 2026 9:05 AM - PR NewsWire
Full Article List
